AGE-RELATED MACULAR DEGENERATION (AMD)

This study is testing two investigational drugs, pozelimab and cemdisiran, to see if they can slow down the progression of geographic atrophy, a late-stage form of age-related macular degeneration that causes permanent central vision loss. The trial will involve about 975 partici…

This study is testing whether a 6-month online stationary bike program can help preserve vision and improve overall health in Veterans with age-related macular degeneration (AMD). Researchers will compare 70 Veterans doing spin cycling against a control group to see if exercise a…

This study is testing whether an oral medication called TECFIDERA® (dimethyl fumarate), already used for multiple sclerosis, can slow the progression of geographic atrophy. Geographic atrophy is a form of 'dry' age-related macular degeneration that causes gradual, irreversible vi…

This study is testing a small implant called the SING IMT™ that acts like a tiny telescope inside the eye. It's designed for people with advanced age-related macular degeneration who have already had cataract surgery. Researchers want to see if this device can safely improve cent…

This study is testing whether an experimental eye injection called ONL1204 can slow the progression of geographic atrophy, a severe form of age-related macular degeneration that causes permanent vision loss. Researchers will compare different doses and schedules of the injection …

This study is observing how well a higher-dose version of an existing eye injection (aflibercept 8mg) works in the first two months for people with 'wet' age-related macular degeneration (AMD). Researchers will track how quickly fluid in the back of the eye decreases and if visio…

This study is testing whether artificial intelligence (AI) software can help family doctors and geriatric specialists better screen for two common causes of vision loss: diabetic eye disease and age-related macular degeneration. About 4,300 adults with diabetes or over age 50 wil…